DEA Announces Intent to Temporarily Place 7-Hydroxymitragynine in Schedule I

The Drug Enforcement Administration (DEA) has issued a notice of intent to publish a temporary order to place 7-hydroxymitragynine, a substance found in kratom, in Schedule I of the Controlled Substances Act. This action is based on a finding that temporary scheduling is necessary to avoid an imminent hazard to public safety, with the temporary order expected to take effect after August 5, 2026.

Context

7-hydroxymitragynine is a compound derived from the kratom plant, which has gained popularity for its purported pain-relieving and mood-enhancing effects. The DEA's action follows increasing scrutiny over the safety of kratom and its derivatives, with some studies linking the substance to adverse health effects. The classification as a Schedule I drug indicates that it is considered to have a high potential for abuse and no accepted medical use.

Why it matters

The DEA's decision to temporarily classify 7-hydroxymitragynine as a Schedule I substance reflects growing concerns about its safety and potential for abuse. This classification could limit access to kratom products for consumers and impact those who use it for pain relief or other therapeutic purposes. The move highlights ongoing debates about regulation and safety in the realm of herbal supplements and alternative medicines.

Implications

If the temporary scheduling takes effect, it could lead to increased enforcement actions against kratom vendors and users. This may significantly impact individuals who rely on kratom for managing chronic pain or other conditions. The decision could also set a precedent for how other herbal supplements are regulated in the future.

What to watch

Following the DEA's announcement, stakeholders, including kratom advocates and health professionals, may mobilize to contest the classification. Public comments and discussions regarding the temporary order are expected to unfold in the lead-up to its implementation. Monitoring legislative responses and potential legal challenges will be crucial in understanding the future of kratom regulation.